

## Exendin-4

<b>Cat. No.:</b>	HY-13443
<b>CAS No.:</b>	141758-74-9
<b>Molecular Formula:</b>	C <sub>184</sub> H <sub>282</sub> N <sub>50</sub> O <sub>60</sub> S
<b>Molecular Weight:</b>	4186.57
<b>Sequence:</b>	His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH <sub>2</sub> <small>HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH<sub>2</sub></small>
<b>Sequence Shortening:</b>	HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH <sub>2</sub>
<b>Target:</b>	Glucagon Receptor
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Protect from light Powder    -80°C    2 years -20°C    1 year * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : 33.33 mg/mL (7.96 mM; Need ultrasonic)  
 DMSO : ≥ 32 mg/mL (7.64 mM)  
 Ethanol : < 1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	0.2389 mL	1.1943 mL	2.3886 mL
	5 mM	0.0478 mL	0.2389 mL	0.4777 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (0.60 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Exendin-4 (Exenatide), a 39 amino acid peptide, is a long-acting glucagon-like peptide-1 receptor agonist with an IC<sub>50</sub> of 3.22

	nM.
<b>IC<sub>50</sub> &amp; Target</b>	IC50: 3.22 nM (glucagon-like peptide-1 receptor) <sup>[1]</sup>
<b>In Vitro</b>	In human umbilical vein endothelial cells, exendin-4 significantly increases NO production, endothelial NO synthase (eNOS) phosphorylation, and GTP cyclohydrolase 1 (GTPCH1) level in a dose-dependent manner <sup>[2]</sup> . Exendin-4 shows cytotoxic effects to MCF-7 breast cancer cells with IC <sub>50</sub> of 5 μM at 48 hour <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Both low- and high-dose exendin-4 treatment in ob/ob mice improve serum ALT and reduce serum glucose, and calculated HOMA scores compared with control. Exendin-4-treated ob/ob mice sustain a marked reduction in the net weight gain in the final 4 weeks of the study period <sup>[4]</sup> . Animals treated with exendin-4 have more pancreatic acinar inflammation, more pyknotic nuclei and weigh significantly less than control rats. Exendin-4 treatment is associated with lower leptin levels as well as lower HOMA values in rats <sup>[5]</sup> . Exenatide causes dose-dependent relaxation of rat thoracic aorta, which is evoked via the GLP-1 receptor and is mediated mainly by H <sub>2</sub> S but also by NO and CO <sup>[6]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## PROTOCOL

### Animal Administration <sup>[4][5]</sup>

Rats: 20 Sprague-Dawley male rats, ten of which are treated with exendin-4 (10 μg/kg) and ten of which are used as controls. The study period is 75 days. Serum and pancreatic tissue are removed for biochemical and histological study. Blood glucose, amylase, lipase and adipocytokines are compared between the two groups<sup>[5]</sup>.

Mice: The exendin-4 treatment groups are treated with 10 μg/kg every 24 hours for the first 14 days. This treatment is the induction phase. Respective control mice (lean and ob/ob) receive saline every 24 hours. After 14 days Exendin-4-treated mice are randomly divided into two groups: one group receives high dose exendin-4 (20 μg/kg) every 12 hours, while the second group continues with low dose exendin-4 (10 μg/kg) every 12 hours. The control mice continue to receive saline every 12 hours. The mice are weighed daily for the 60-day treatment period<sup>[4]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## CUSTOMER VALIDATION

- Gut. 2022 Jun 13;gutjnl-2021-326541.
- Biomaterials. 2021, 120944.
- Br J Pharmacol. 2020 Aug;177(15):3389-3402.
- J Invest Dermatol. 2021 Oct 20;S0022-202X(21)02369-1.
- BMC Biol. 2021 Mar 3;19(1):40.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Doyle ME, et al. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept. 2003 Jul 15;114(2-3):153-8.

[2]. Wei R, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Endocrinol Metab. 2016 Jun 1;310(11):E947-57.

- 
- [3]. Fidan-Yaylall G, et al. Antidiabetic exendin-4 activates apoptotic pathway and inhibits growth of breast cancer cells. *Tumour Biol.* 2016 Feb;37(2):2647-53.
- [4]. Ding X, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/obmice. *Hepatology.* 2006 Jan;43(1):173-81.
- [5]. Nachnani JS, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. *Diabetologia.* 2010 Jan;53(1):153-9.
- [6]. Selley E, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. *Cardiovasc Diabetol.* 2014 Apr 2;13:69.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**